Coronavirus and the Heart: How Should Cardiologists Prepare?

As the number of confirmed cases increases throughout the globe, a picture is emerging as to what the direct cardiovascular effects of this pandemic may be.

Coronavirus y corazón ¿Cómo deben prepararse los cardiólogos?

World-renowned physicians such as Alaide Chieffo (from the San Raffaele Hospital, Milan, Italy) have declared that coronavirus came completely unexpected and has put healthcare systems on the verge of a breakdown. The number of beds, the intensive care units, supplies and equipment for mechanical ventilation are all limited, and so is the protective equipment for physicians. Consequently, slowing down the contagion rate is absolutely fundamental.

In the meantime, elective interventional cardiology procedures have been reduced by 80% in referral hospitals that are now caring for the growing needs of coronavirus patients.


Read also: ACC Recommendations against the New Coronavirus.


There were early warnings that myocarditis might be one manifestation of COVID-19 infection. However, physicians such as Junbo Ge, who studied this phenomenon directly in Wuhan City, China, did not see any signs of direct virus infiltration of the myocardium in an electron microscope.

There is, however, a considerable proportion of patients with coronavirus infection who do have elevation of troponin, but that does not indicate myocardial injury: we are dealing with multiorgan damage, and the heart is just another victim.

Many patients, after recovering from coronavirus infection, present evidence of lung fibrosis, but no myocardial injury, since the troponin and pro-BNP elevation normalize after discharge.


Read also: Coronavirus | Recommendations to Stop the Pandemic.


Last week, SOLACI published the first recommendations of the American College of Cardiology (ACC) on cardiac complications and comorbidities of COVID-19 infection. In that document, the ACC highlighted that most patients hospitalized with the virus had a history of cardiovascular, cerebrovascular, and diabetes-related comorbidities.

A report from China, published in the Lancet, showed that 40% of all admitted patients had a history of cardiovascular or cerebrovascular disease, and 12% had diabetes. JAMA published something similar: nearly half of the patients had at least one comorbid condition, such as hypertension, diabetes, or cardiovascular disease.

Some observations regarding flu season could be replicated for COVID-19. For example, during flu season there are more implantable cardioverter defibrillator shocks. With generalized inflammation as a trigger, similar situations might be expected with COVID-19.


Read also: EVAR with No Complications in Octogenarians: Survival Rate Identical to that of Healthy Octogenarians.


The same might happen with any heart failure exacerbations.

There are approximately 80 trials now recruiting patients for studies testing antiviral agents and vaccines, while trying to understand the whole disease process.

In the meantime, as cardiologists, the most important thing for us seems to be abiding by clinical practice guidelines as regards prevention, particularly secondary prevention. The lower the baseline risk, the lower the risk of events in case of an infection with this new virus.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...